Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Genet Med. 2020 Dec;22(12):2081-2088. doi: 10.1038/s41436-020-0925-z. Epub 2020 Aug 10.
Biallelic germline mismatch repair (MMR) gene pathogenic variants (PVs) cause constitutional MMR deficiency (CMMRD), a highly penetrant childhood cancer syndrome phenotypically overlapping with neurofibromatosis type 1 (NF1). CMMRD testing in suspected NF1 children without NF1/SPRED1 PVs enables inclusion of CMMRD positives into monitoring programs prior to tumor onset. However, testing is associated with potential harms and the prevalence of CMMRD among these children is unknown.
Using a simple and scalable microsatellite instability (MSI) assay of non-neoplastic leukocyte DNA to detect CMMRD, we retrospectively screened >700 children suspected of sporadic NF1 but lacking NF1/SPRED1 PVs.
For three of seven MSI-positive patients germline MMR gene PVs confirmed the diagnosis of CMMRD. Founder variants NM_000535.5(PMS2):c.736_741delinsTGTGTGTGAAG, prevalent in Europe and North America, and NM_000179.2(MSH6):c.10C>G, affecting 1:400 French Canadians, represented two of five PVs. The prevalence of CMMRD was 3/735 (0.41%, 95% confidence interval [CI]: 0.08-1.19%).
Our empirical data provide reliable numbers for genetic counseling and confirm previous prevalence estimations, on which Care for CMMRD consortium guidelines are based. These advocate CMMRD testing of preselected patients rather than offering reflex testing to all suspected sporadic NF1 children lacking NF1/SPRED1 PVs. The possibility of founder effects should be considered alongside these testing guidelines.
双等位基因生殖系错配修复(MMR)基因致病性变异(PVs)导致结构MMR 缺陷(CMMRD),这是一种具有高外显率的儿童期癌症综合征,表型与神经纤维瘤病 1 型(NF1)重叠。在无 NF1/SPRED1 PVs 的疑似 NF1 儿童中进行 CMMRD 检测,可在肿瘤发生前将 CMMRD 阳性患者纳入监测计划。然而,检测与潜在危害相关,并且这些儿童中 CMMRD 的患病率尚不清楚。
使用非肿瘤性白细胞 DNA 的简单且可扩展的微卫星不稳定性(MSI)检测来检测 CMMRD,我们回顾性筛选了>700 名疑似散发 NF1 但缺乏 NF1/SPRED1 PVs 的儿童。
在 7 名 MSI 阳性患者中的 3 名中,生殖系 MMR 基因 PVs 证实了 CMMRD 的诊断。在欧洲和北美的流行变体 NM_000535.5(PMS2):c.736_741delinsTGTGTGTGAAG 和影响 1:400 法国加拿大人群的 NM_000179.2(MSH6):c.10C>G 代表了五个 PVs 中的两个。CMMRD 的患病率为 3/735(0.41%,95%置信区间[CI]:0.08-1.19%)。
我们的经验数据为遗传咨询提供了可靠的数字,并证实了之前的患病率估计值,Care for CMMRD 联盟指南就是基于这些估计值。这些指南主张对预先选定的患者进行 CMMRD 检测,而不是对所有缺乏 NF1/SPRED1 PVs 的疑似散发 NF1 儿童进行反射性检测。在这些检测指南中应考虑到创始效应的可能性。